within Pharmacolibrary.Drugs.ATC.N;

model N05CF03
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.3,
    Cl             = 0.065,
    adminDuration  = 600,
    adminMass      = 0.01,
    adminCount     = 1,
    Vd             = 0.0014,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.03666666666666667,
    Tlag           = 10.200000000000001
  );

  annotation(Documentation(
    info ="<html><body><p>Zaleplon is a nonbenzodiazepine hypnotic agent used for the short-term treatment of insomnia. It acts as a selective agonist at the benzodiazepine site of the GABA-A receptor complex, enhancing GABAergic inhibition. Zaleplon is FDA-approved for use in adults with difficulty falling asleep, and is currently available in several countries.</p><h4>Pharmacokinetics</h4><p>Typical pharmacokinetic parameters in healthy adult volunteers, both sexes, after single oral dose.</p><h4>References</h4><ol><li><p>Rosen, AS, et al., &amp; Troy, SM (1999). Zaleplon pharmacokinetics and absolute bioavailability. <i>Biopharmaceutics &amp; drug disposition</i> 20(3) 171–175. DOI:<a href=&quot;https://doi.org/10.1002/(sici)1099-081x(199904)20:3&lt;171::aid-bdd169&gt;3.0.co;2-k&quot;>10.1002/(sici)1099-081x(199904)20:3&lt;171::aid-bdd169&gt;3.0.co;2-k</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/10211871/&quot;>https://pubmed.ncbi.nlm.nih.gov/10211871</a></p></li><li><p>Ali, SA, et al., &amp; Alqahtani, T (2022). Rapid oral transmucosal delivery of zaleplon-lavender oil utilizing self-nanoemulsifying lyophilized tablets technology: development, optimization and pharmacokinetic evaluation. <i>Drug delivery</i> 29(1) 2773–2783. DOI:<a href=&quot;https://doi.org/10.1080/10717544.2022.2115165&quot;>10.1080/10717544.2022.2115165</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/36036168/&quot;>https://pubmed.ncbi.nlm.nih.gov/36036168</a></p></li><li><p>Sanchez Garcia, P, et al., &amp; Darwish, M (2000). Effect of zaleplon on digoxin pharmacokinetics and pharmacodynamics. <i>American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists</i> 57(24) 2267–2270. DOI:<a href=&quot;https://doi.org/10.1093/ajhp/57.24.2267&quot;>10.1093/ajhp/57.24.2267</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/11146970/&quot;>https://pubmed.ncbi.nlm.nih.gov/11146970</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end N05CF03;
